Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.

Summary

GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. The purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of GW842166X in healthy male and female volunteers.

Timeline

Start

2007-09

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “Compound terminated”

Drugs

Indications

No indication recorded.